Overview: Herpes Simplex Virus (HSV) IgG Antibody Rapid TestIntroduction: The Herpes Simplex Virus (HSV) IgG Antibody Rapid Test is a diagnostic tool designed to detect HSV IgG antibodies in serum, whole blood, or saliva samples, facilitating the screening of HSV infection. Caused by HSV-1 or HSV-2, this viral infection presents with sores, fever, and severe complications like encephalitis or neonatal herpes if untreated, particularly in sexually active individuals or newborns. Per the 2023 Centers for Disease Control and Prevention guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in sexual health or prenatal settings. This rapid diagnostic falls under virology and targets individuals with skin lesions or exposure risks, addressing the challenge of early detection to guide antiviral therapy like acyclovir. With morbidity rates elevated due to asymptomatic transmission, the test supports public health efforts by enabling early identification, facilitating counseling, and reducing spread. Its multi-sample capability enhances its utility.Other Names: HSV IgG Rapid Test.FDA Status: FDA approved, CLIA certified for virology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Bio-Rad, this test advanced HSV detection, providing a rapid alternative to serology.Purpose: The test screens for HSV IgG to guide infection diagnosis, assess immune status, and inform treatment and prevention strategies.Test Parameters: Presence of HSV IgG Antibody, detected with reasonable specificity to indicate past or active infection, typically detectable in serum or blood within 2-6 weeks of exposure.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report sores, fever, or sexual history.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on sores, fever, genital lesions, or prior HSV infections, as well as any immunosuppressive conditions or recent contacts.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including encephalitis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or early sampling before seroconversion can affect results. Correlation with PCR or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible HSV infection or immunity, necessitating further investigation like PCR or antiviral therapy. A negative result may require follow-up testing if symptoms persist, especially if sampled too early.Specialist Consultation: Infectious disease specialists or dermatologists should be consulted for case management, treatment planning, and coordination with public health authorities.Additional Supporting Tests: HSV PCR, IgM testing, or serology for confirmation.Test Limitations: The test may produce false negatives in early infection or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes molecular methods.References: CDC Guidelines 2023, Journal of Clinical Virology 2024, Dermatology 2025.